Streamline Your Cell Line Screening: With the Automated, Microscale, Stirred Tank, Single-Use Bioreactor

by Tim Ward
Volume 13, Issue 4 (Winter 2014/2015)

The price per patient for protein-based and monoclonal antibody (mAb) therapies runs into thousands of dollars per patient each year. These therapies cost considerably more to manufacture than small molecules. Hence, if mammalian or insect cell lines expressing high protein titres can be selected and optimized for protein expression using microscale bioreactor models early in development, then manufacturing costs can be reduced significantly...

Ward T. Streamline your cell line screening: with the automated, microscale, stirred tank, single-use bioreactor. BioProcess J, 2015; 13(4): 60–1.

Posted online January 20, 2015.